Soriot’s Vision For AZ: A Focused Innovation-Driven Biopharma

 
• By Jessica Merrill

AstraZeneca will accelerate development of several mid-stage assets into Phase III and turn aggressively to business development under CEO Pascal Soriot’s strategy to transform the company, even as it shores up its P&L with more job cuts.

More from Archive

More from Pink Sheet